Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

Shorla Oncology

Shorla Oncology at ASHP Mid Year 2024, New Orleans, Dec 8-12

November 13th 2024November 11th 2024

Read More

Banner

Frontiers Health 2024

October 10th 2024

Read More

Banner

Shorla Oncology at CPHI Milan

September 23rd 2024

Read More

Banner
September 11th 2024September 11th 2024

Read More

Logo

Shorla Oncology Announces FDA Approval for TEPYLUTE, A Novel Formulation to Treat Breast and Ovarian Cancer

September 25th 2024July 2nd 2024

Read More

Banner

Enterprise Ireland Start-up Day 2024

May 17th 2024

Read More

Banner

SHORLA ONCOLOGY TO ATTEND ASEMBIA24

April 24th 2024April 24th 2024

Read More

Sharon Cunningham

MassBio | SHARON CUNNINGHAM

April 24th 2024April 24th 2024

Read More

Banner

Sharon Cunningham & Orlaith Ryan are 2024 EY Entrepreneur Of The Year Finalists

April 24th 2024

Read More

Older posts
Newer posts
Page1 Page2 Page3 Page4 … Page12
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.